Gyre Therapeutics is trading at $6.38, down 10.01%, with broader market weakness possibly adding pressure; no clear company-specific announcement explains the decline.
- On October 29, 2026, the investor-relations page’s latest release is dated September 3.
- U.S. stocks are lower, with the Nasdaq Composite down more than 1.5% amid technology-sector pressure following Alphabet’s earnings and concerns about AI spending.